• Citron Research’s Andrew Left takes a short position on Palantir, calling the stock 'obvious' and 'beyond overvalued.'
  • Palantir’s Q2 2025 results show strong revenue growth, particularly in U.S. commercial and government segments.
  • The debate highlights broader concerns about AI-sector valuations, with analysts divided on sustainability.

Citron’s Short Bet Against Palantir

Andrew Left of Citron Research has publicly disclosed a short position in Palantir Technologies (PLTR), labeling the stock "beyond overvalued" despite acknowledging the company’s strong business fundamentals and leadership under CEO Alex Karp. The move underscores persistent skepticism around Palantir’s valuation, even as its financial performance continues to impress.

Left, known for his high-profile short campaigns, described the trade as "obvious" in a recent statement, though he emphasized respect for Palantir’s technology and management. The announcement has reignited debates about whether the company’s premium valuation—bolstered by AI hype and government contracts—is justified.

Palantir’s Growth Momentum

Palantir’s Q2 2025 earnings revealed a 48% year-over-year revenue jump, with U.S. commercial revenue surging 68% to $733 million. The company raised its full-year guidance, now projecting 45% revenue growth, while U.S. commercial revenue is expected to climb 85%. These figures have fueled bullish sentiment, but Citron’s short bet suggests not all investors are convinced.

"The numbers are impressive, but the multiple is stretched," said one hedge fund analyst, speaking on condition of anonymity. "Palantir trades at a significant premium to peers, and any slowdown in AI adoption or government spending could pressure the stock."

Market Reaction and Broader Implications

Palantir’s shares dipped slightly following Citron’s announcement, though the broader AI rally has cushioned the impact. The short call reflects a recurring theme in 2024–2025: high-flying tech stocks facing scrutiny over valuation sustainability. Other AI-focused firms have similarly been targeted by short sellers amid lofty multiples.

Left’s move also highlights the divergence between operational performance and market pricing. While Palantir’s growth trajectory is robust, its valuation—trading at over 20x forward sales—leaves little room for error. "This isn’t about the business; it’s about the price," Left remarked.

Attempts to reach Palantir for comment were unsuccessful. The company’s next earnings report, due in November, will be closely watched for signs of continued momentum or potential cracks in the growth story.